Urea for the Treatment of Hyponatremia
- PMID: 30181129
- PMCID: PMC6237061
- DOI: 10.2215/CJN.04020318
Urea for the Treatment of Hyponatremia
Abstract
Background and objectives: Current therapies for hyponatremia have variable effectiveness and tolerability, and in certain instances, they are very expensive. We examined the effectiveness, safety, and tolerability of urea for the treatment of inpatient hyponatremia.
Design, setting, participants, & measurements: We identified all patients hospitalized at the University of Pittsburgh Medical Center between July 2016 and August 2017 with hyponatremia (plasma sodium <135 mEq/L) who received urea, including a subgroup of patients who received urea as the sole drug therapy for hyponatremia (urea-only treated). We matched urea only-treated patients to a group of patients with hyponatremia who did not receive urea (urea untreated) and compared changes in plasma sodium at 24 hours and the end of therapy as well as the proportion of patients who achieved plasma sodium ≥135 mEq/L. We abstracted data on adverse events and reported side effects of urea.
Results: Fifty-eight patients received urea (7.5-90 g/d) over a median of 4.5 (interquartile range, 3-8) days and showed an increase in plasma sodium from 124 mEq/L (interquartile range, 122-126) to 131 mEq/L (interquartile range, 127-134; P<0.001). Among 12 urea only-treated patients, plasma sodium increased from 125 mEq/L (interquartile range, 122-127) to 131 mEq/L (interquartile range, 129-136; P=0.001) by the end of urea therapy. There was a larger increase in plasma sodium at 24 hours in urea only-treated patients compared with urea-untreated patients (2.5 mEq/L; interquartile range, 0-4.5 versus -0.5 mEq/L; interquartile range, -2.5 to 1.5; P=0.04), with no difference in change in plasma sodium by the end of therapy (6 mEq/L; interquartile range, 3.5-10 versus 5.5 mEq/L; interquartile range, 3-7.5; P=0.51). A greater proportion of urea only-treated patients achieved normonatremia, but this difference was not statistically significant (33% versus 8%; P=0.08). No patients experienced overly rapid correction of plasma sodium, and no serious adverse events were reported.
Conclusions: Urea seems effective and safe for the treatment of inpatient hyponatremia, and it is well tolerated.
Keywords: hyponatremia; inappropriate ADH syndrome; urea.
Copyright © 2018 by the American Society of Nephrology.
Figures
Similar articles
-
Comparative Safety and Effectiveness of Urea and Tolvaptan for the Management of Hyponatremia.J Pharm Pract. 2024 Dec;37(6):1252-1257. doi: 10.1177/08971900241247617. Epub 2024 Apr 23. J Pharm Pract. 2024. PMID: 38652561
-
Treatment of euvolemic hyponatremia in the intensive care unit by urea.Crit Care. 2010;14(5):R184. doi: 10.1186/cc9292. Epub 2010 Oct 14. Crit Care. 2010. PMID: 20946646 Free PMC article.
-
Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.Am J Kidney Dis. 2018 Jun;71(6):772-782. doi: 10.1053/j.ajkd.2017.12.002. Epub 2018 Feb 23. Am J Kidney Dis. 2018. PMID: 29478867 Free PMC article.
-
Diagnosis and Management of Hyponatremia: A Review.JAMA. 2022 Jul 19;328(3):280-291. doi: 10.1001/jama.2022.11176. JAMA. 2022. PMID: 35852524 Review.
-
Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications.Clin Nephrol. 1996 Sep;46(3):149-69. Clin Nephrol. 1996. PMID: 8879850 Review.
Cited by
-
Empagliflozin: a wonder drug for the treatment of SIAD?Front Endocrinol (Lausanne). 2024 Oct 7;15:1453159. doi: 10.3389/fendo.2024.1453159. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39435353 Free PMC article. No abstract available.
-
[Consensus recommendations on the diagnosis and treatment of hyponatremia from the Austrian Society for Nephrology 2024].Wien Klin Wochenschr. 2024 Feb;136(Suppl 1):1-33. doi: 10.1007/s00508-024-02325-5. Epub 2024 Feb 29. Wien Klin Wochenschr. 2024. PMID: 38421476 Free PMC article. German.
-
Use of Urea for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: A Systematic Review.JAMA Netw Open. 2023 Oct 2;6(10):e2340313. doi: 10.1001/jamanetworkopen.2023.40313. JAMA Netw Open. 2023. PMID: 37902751 Free PMC article.
-
Endocrinologists at work: management of hyponatremia in clinical practice.J Endocrinol Invest. 2023 Dec;46(12):2453-2457. doi: 10.1007/s40618-023-02147-8. Epub 2023 Jul 15. J Endocrinol Invest. 2023. PMID: 37452912 No abstract available.
-
Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer.Endocr Oncol. 2022 Jul 11;2(1):R78-R89. doi: 10.1530/EO-22-0056. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435459 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
